The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study

By  

Cerebrovascular Diseases, Vol. 20, Iss. 5, 2005-11 ,pp. : 304-309

Karger

Access to resources Recommend Favorite

Effect of the Glycine Antagonist Gavestinel on Cerebral Infarcts in Acute Stroke Patients, a Randomized Placebo-Controlled Trial: The GAIN MRI Substudy

By  

Cerebrovascular Diseases, Vol. 21, Iss. 1-2, 2006-01 ,pp. : 106-111

Karger

Access to resources Recommend Favorite

Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial

By  

Cerebrovascular Diseases, Vol. 11, Iss. 1, 2001-01 ,pp. : 20-29

Karger

Access to resources Recommend Favorite

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

By Nyhlin H.   Bang C.   Elsborg L.   Silvennoinen J.   Holme I.   Rüegg P.   Jones J.   Wagner A.  

Scandinavian Journal of Gastroenterology, Vol. 39, Iss. 2, 2004-02 ,pp. : 119-126

Informa Healthcare

Access to resources Recommend Favorite

A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine Neuroaid (MLC 601) in Enhancing Recovery after Stroke (TIERS)

By  

Cerebrovascular Diseases, Vol. 28, Iss. 5, 2009-10 ,pp. : 514-521

Karger

Access to resources Recommend Favorite